Back to Search
Start Over
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study
- Source :
- Ocular Immunology and Inflammation. 29:1621-1626
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- This study evaluated the efficacy and safety of once-daily Alcaftadine 0.25% (AGN-229666) for prevention of signs and symptoms of Japanese cedar-pollen allergic conjunctivitis. This was a single-ce...
- Subjects :
- Adult
Male
Histamine H1 Antagonists, Non-Sedating
medicine.medical_specialty
Cryptomeria
Administration, Ophthalmic
Signs and symptoms
law.invention
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
law
medicine
Humans
Immunology and Allergy
Prospective Studies
Olopatadine Hydrochloride
Conjunctivitis, Allergic
030203 arthritis & rheumatology
business.industry
Imidazoles
Allergens
Benzazepines
Middle Aged
Olopatadine
medicine.disease
Dermatology
Allergic conjunctivitis
Cedar pollen
Ophthalmology
Treatment Outcome
Histamine H1 Antagonists
030221 ophthalmology & optometry
Pollen
Female
Ophthalmic Solutions
Alcaftadine
Once daily
business
medicine.drug
Subjects
Details
- ISSN :
- 17445078 and 09273948
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Ocular Immunology and Inflammation
- Accession number :
- edsair.doi.dedup.....7d5ef9152582c43d6931e01341299432
- Full Text :
- https://doi.org/10.1080/09273948.2020.1760309